Estimating Infarct Size in the Troponin Era: Why No Biomarker Has Replaced Creatine Kinase-Myocardial Band Area Under the Curve (CK-MB AUC) and Where the Field Must Go Next.

Authors

Alec J Lippmann, Ali Qureshi, Mujtaba Khan, Musa Azhar, Fawaz Qazi, Muhammad Awan, Stuart Tauberg

Published in

Cureus. Volume 18. Issue 5. Pages e109879. Epub May 29, 2026.

Abstract

Infarct size remains a clinically meaningful determinant of prognosis after myocardial infarction (MI) and an important surrogate endpoint in cardiovascular research. Although cardiac troponins have appropriately replaced creatine kinase-myocardial band (CK-MB) for diagnosis because of superior sensitivity and specificity, they have not replaced the quantitative role historically served by serial CK-MB area-under-the-curve (AUC) analysis. Troponin release is prolonged, assay-dependent, and frequently influenced by baseline myocardial injury, making cumulative troponin exposure difficult to interpret as a direct measure of infarct mass. Imaging modalities, especially late gadolinium enhancement cardiac magnetic resonance (CMR), provide accurate infarct characterization but are limited by cost, access, timing, workflow, and scalability. This narrative review revisits the historical utility of CK-MB AUC, explains why troponin has not provided an equivalent biomarker-based infarct-size estimate, and argues for renewed development of practical biomarker strategies, including kinetic modeling, multi-marker panels, and novel biomarkers designed specifically for infarct-size quantification.

PMID:
42371427
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.